ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0655

Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis

Rosa Morlà1, Beatriz Frade-Sosa2, Núria Sapena3, Roberto Gumucio2, Raimon Sanmarti2 and Jose A Gomez-Puerta2, 1Hospital Universitari Clinic de Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Rheumatology Department, Hospital Clínic, Barcelona, Spain

Meeting: ACR Convergence 2021

Keywords: depression, Fatigue, PRO, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2) respectively. However, the factors that determine these comorbidities, especially their association with disease activity have been little studied.

We studied these two comorbidities: depression and fatigue in patients with RA, according to clinical activity, and the association between them.

Methods: Patients with RA (ACR/EULAR criteria, 2010) who agreed to participate in this study were included consecutively in the Rheumatology Department during a period of 3 months.

Demographic variables (age, sex, BMI), years of disease duration, treatment, physical examination (TJC28, SJC28), patient (PATGL) and physician (PhyGL) global assessment, and laboratory tests (ESR, CRP) were collected. Patients completed 2 one-dimensional questionnaires: PHQ-9 for depression (0-27; cut-off point>10) and FACIT-F for fatigue (0-52; lower scores indicate more fatigue) and the multidimensional health assessment questionnaire (MDHAQ) which includes a query for depression in the checklist review of 60 symptoms (ROS60) and one for fatigue measured in VAS of 0-10 (VAS_Fatigue). EULAR composite indices for clinical activity (DAS28-ESR and CRP, CDAI, SDAI) and self-reported clinical activity index with RAPID3 = function (FN) + pain (PN) + VGP were calculated.

Patients were compared in two groups according to disease activity (DAS28-ESR). Group 1: > 3.2 = moderate or high activity, and group 2: ≤3.2 = low activity or remission.

A bivariate statistical analysis was performed to compare groups (U Mann Whitney-test for quantitative variables and Chi2-test for categorical). Finally, Spearman’s Rho correlation was done.

Results: A total of 75 patients with RA were studied with a median of 14 years (IQR: 8-24) of disease duration, 84% women, with a median age of 63 (36-88) years and a BMI median of 24.22 (IQR: 22-27.4) and 64% with DMARDb treatment. 19 patients had moderate or high activity and 56 patients with low activity or remission. The clinical variables: TSC, SJC, laboratory tests (ESR, CRP) and all self-reported variables in MDHAQ (PN, FN, PTGL, self-RADAI, VAS_Fatigue, ROS60), PhyGL, FACIT-F and PHQ-9 showed significant differences between the two groups, with higher scores in patients of group 1. Also in the composite indices, as we expected (Table 1).

FACIT-F scores showed a very good negative correlation with VAS_Fatigue (r = -0.802; p < 0.0001), PHQ-9 (r = -0.850; p < 0.0001) and ROS60 (r = -0.766; p < 0.0001) and almost good with the rest of the variables (table 2). PHQ-9 scores showed high positive correlation with all the variables studied, remarkable in VAS_Fatigue (r= 0.721; p < 0.001) and in ROS60 (r = 0.717; p < 0.001) (Table 2).

Conclusion: In RA patients with a higher burden of disease (clinical, biological and self-reported) were observed high scores for fatigue and depression with a strong association to each other. These two comorbidities should be routinely studied in the follow-up of active RA patients.

References
1.Matcham F, et al. Rheumatology (Oxford) 2013.
2.Tournadre A, et al. Joint Bone Spine. 2019.


Disclosures: R. Morlà, None; B. Frade-Sosa, None; N. Sapena, None; R. Gumucio, None; R. Sanmarti, Abbvie, 6, BMS, 5, BMS, 6, Sandoz, 6, Pfizer, 6, Roche, 6, MSD, 6; J. Gomez-Puerta, Abbvie, 6, BMS, 6, GSK, 6, Galapagos, 6, Lilly, 6, MSD, 6, Pfizer, 6, Roche, 6, Sanofi, 1.

To cite this abstract in AMA style:

Morlà R, Frade-Sosa B, Sapena N, Gumucio R, Sanmarti R, Gomez-Puerta J. Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/depression-and-fatigue-two-forgotten-associated-comorbidities-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-and-fatigue-two-forgotten-associated-comorbidities-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology